Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.

ABSTRACT: Recent clinical trials have shown that the use of the HIV-1 integrase (IN) inhibitor raltegravir (RAL) results in drops in the viral load that are more rapid than those achieved by use of the reverse transcriptase (RT) inhibitor efavirenz. Previously, mathematical modeling of viral load decay that takes into account the stage of viral replication targeted by a drug has yielded data that closely approximate the clinical trial results. This model predicts greater inhibition of viral replication by drugs that act later in the viral replication cycle. In the present study, we have added drugs that target entry, reverse transcription, integration, or proteolytic processing to acutely infected cells and have shown modest viral inhibition by entry inhibitors, intermediate levels of inhibition by

SUBMITTER: Donahue DA 

PROVIDER: S-EPMC2826010 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature